Skip to main content
PR Newswire (US) — Real Estate·HK·

Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth

Results Highlights for Interim Results ended 30 June 2026 Revenue reached RMB1,006.5 million, increasing by 21.0% YoY Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY Gross profit margin was 34.0% HONG KONG, Aug. 27, 2026 /PRNewswire/ -- On August 26, 2026, Viva Biotech...

Read releases like this the second they cross the wire.

1,200+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 7-day free trial, no card required.

Start the free trial →

Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.

PPN Source →
Shared via PPN World — real-time press release intelligence.
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth · PR Newswire (US) — Real Estate · PPN World